Obsessive Compulsive Disorder (OCD)

Also known as: Obsessive-Compulsive Disorder (OCD) / Obsessive Compulsive Disorder / Obsessive-Compulsive Disorder / Obsessive Compulsive Disorders / Obsessive-compulsive disorders / OCD / [X]Obsessive-compulsive disorder, unspecified / Obsessive-compulsive reaction / Reaction obsessive-compulsive / Obsessive-compulsive neurosis / Anancastic neurosis

DrugDrug NameDrug Description
DB00215CitalopramCitalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230].
DB01242ClomipramineClomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.
DB01175EscitalopramEscitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD).
DB00472FluoxetineFluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Fluoxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI.
DB00176FluvoxamineFluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
DB00502HaloperidolA phenyl-piperidinyl-butyrophenone, traditional antipsychotic drug that is used primarily to treat schizophrenia and other psychoses. It is also used for the management of schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea associated with Huntington's disease. It is a potent antiemetic and is used in the treatment of intractable hiccups [L1994], [L1996]. The efficacy of haloperidol was first established in controlled trials in the 1960s [L2014]. Interestingly, in vivo pharmacogenetic studies have demonstrated that the metabolism of haloperidol may be modulated by genetically determined polymorphic _CYP2D6_ activity. However, these findings contradict the findings from studies in vitro with human liver microsomes and from drug interaction studies in vivo. Inter-ethnic and pharmacogenetic differences in haloperidol metabolism may possibly explain these observations [A32346].
DB00715ParoxetineParoxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize ⍺- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation.
DB01224QuetiapineQuetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.
DB01104SertralineSertraline hydrochloride belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake [T28]. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a more detailed listing of side effects). Compared to other agents in this class, sertraline may cause greater diarrheal and male sexual dysfunction effects [A1844]. Sertraline displays a better safety or tolerability profile than other classes of antidepressants [A1846]. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants or monoamine oxidase inhibitors [T28]. Sertraline has shown therapeutic effectiveness as a treatment for major depressive disorder [A1836], obsessive-compulsive disorder (OCD) [A1838], panic disorder, post-traumatic stress disorder (PTSD) [A1841], premenstrual dysphoric disorder (PMDD) [A1842] and social anxiety disorder (social phobia).
DB01323St. John's WortNot Available
DrugDrug NameTargetType
DB00215CitalopramSodium-dependent serotonin transportertarget
DB00215CitalopramCytochrome P450 2C19enzyme
DB00215CitalopramCytochrome P450 2D6enzyme
DB00215CitalopramCytochrome P450 3A4enzyme
DB00215CitalopramMultidrug resistance protein 1transporter
DB00215CitalopramCytochrome P450 1A2enzyme
DB00215CitalopramHistamine H1 receptortarget
DB01242ClomipramineSodium-dependent serotonin transportertarget
DB01242ClomipramineSodium-dependent noradrenaline transportertarget
DB01242ClomipramineGlutathione S-transferase Ptarget
DB01242Clomipramine5-hydroxytryptamine receptor 2Atarget
DB01242ClomipramineCytochrome P450 1A2enzyme
DB01242ClomipramineCytochrome P450 2D6enzyme
DB01242ClomipramineCytochrome P450 2C19enzyme
DB01242ClomipramineMultidrug resistance protein 1transporter
DB01242ClomipramineCytochrome P450 3A4enzyme
DB01242Clomipramine5-hydroxytryptamine receptor 2Btarget
DB01242Clomipramine5-hydroxytryptamine receptor 2Ctarget
DB01242ClomipramineSerum albumincarrier
DB01175EscitalopramSodium-dependent serotonin transportertarget
DB01175EscitalopramCytochrome P450 3A4enzyme
DB01175EscitalopramCytochrome P450 2D6enzyme
DB01175EscitalopramSodium-dependent dopamine transportertarget
DB01175EscitalopramSodium-dependent noradrenaline transportertarget
DB01175EscitalopramAlpha-1A adrenergic receptortarget
DB01175EscitalopramMuscarinic acetylcholine receptor M1target
DB01175EscitalopramHistamine H1 receptortarget
DB01175EscitalopramCytochrome P450 2C19enzyme
DB00472FluoxetineSodium-dependent serotonin transportertarget
DB00472FluoxetineCytochrome P450 2C9enzyme
DB00472FluoxetineCytochrome P450 2D6enzyme
DB00472FluoxetineCYP2B proteinenzyme
DB00472FluoxetineCytochrome P450 1A2enzyme
DB00472FluoxetineCytochrome P450 3A4enzyme
DB00472FluoxetineCytochrome P450 2C19enzyme
DB00472FluoxetineMultidrug resistance protein 1transporter
DB00472FluoxetineCytochrome P450 2B6enzyme
DB00472FluoxetineCytochrome P450 3A5enzyme
DB00472FluoxetineSerum albumincarrier
DB00472FluoxetineAlpha-1-acid glycoprotein 1carrier
DB00472FluoxetinePotassium voltage-gated channel subfamily H member 2target
DB00472Fluoxetine5-hydroxytryptamine receptor 2Ctarget
DB00472FluoxetineCyclin-dependent kinases regulatory subunit 1target
DB00472FluoxetineNeuronal acetylcholine receptor subunit alpha-2target
DB00472FluoxetineNeuronal acetylcholine receptor subunit alpha-3target
DB00472FluoxetineNeuronal acetylcholine receptor subunit beta-4target
DB00176FluvoxamineSodium-dependent serotonin transportertarget
DB00176FluvoxamineCytochrome P450 1A2enzyme
DB00176FluvoxamineCytochrome P450 2D6enzyme
DB00176FluvoxamineCytochrome P450 2C9enzyme
DB00176FluvoxamineCytochrome P450 2C19enzyme
DB00176FluvoxamineCytochrome P450 1A1enzyme
DB00176FluvoxamineCytochrome P450 3A4enzyme
DB00176FluvoxamineCytochrome P450 3A5enzyme
DB00176FluvoxamineCytochrome P450 3A7enzyme
DB00176FluvoxamineMultidrug resistance protein 1transporter
DB00176FluvoxamineCytochrome P450 2B6enzyme
DB00176FluvoxamineCytochrome P450 2E1enzyme
DB00176FluvoxaminePotassium voltage-gated channel subfamily H member 2target
DB00176FluvoxamineCytochrome P450 2C8enzyme
DB00176FluvoxamineBile salt export pumptransporter
DB00502HaloperidolD(2) dopamine receptortarget
DB00502HaloperidolGlutamate receptor ionotropic, NMDA 2Btarget
DB00502HaloperidolD(1A) dopamine receptortarget
DB00502HaloperidolCytochrome P450 1A2enzyme
DB00502HaloperidolCytochrome P450 2D6enzyme
DB00502Haloperidol5-hydroxytryptamine receptor 2Atarget
DB00502HaloperidolD(3) dopamine receptortarget
DB00502HaloperidolCytochrome P450 3A4enzyme
DB00502HaloperidolCytochrome P450 3A5enzyme
DB00502HaloperidolCytochrome P450 3A7enzyme
DB00502HaloperidolMultidrug resistance protein 1transporter
DB00502HaloperidolCarbonyl reductase [NADPH] 1enzyme
DB00502HaloperidolUDP-glucuronosyltransferase 1-9enzyme
DB00502HaloperidolCytochrome P450 1A1enzyme
DB00502HaloperidolCytochrome P450 2C19enzyme
DB00502HaloperidolCytochrome P450 2C9enzyme
DB00502HaloperidolMelanin-concentrating hormone receptor 1target
DB00502HaloperidolSynaptic vesicular amine transportertarget
DB00715ParoxetineSodium-dependent serotonin transportertarget
DB00715ParoxetineSodium-dependent noradrenaline transportertarget
DB00715Paroxetine5-hydroxytryptamine receptor 2Atarget
DB00715ParoxetineCytochrome P450 2D6enzyme
DB00715ParoxetineMuscarinic acetylcholine receptor M1target
DB00715ParoxetineMuscarinic acetylcholine receptor M2target
DB00715ParoxetineMuscarinic acetylcholine receptor M3target
DB00715ParoxetineMuscarinic acetylcholine receptor M4target
DB00715ParoxetineMuscarinic acetylcholine receptor M5target
DB00715ParoxetineCytochrome P450 2C9enzyme
DB00715ParoxetineMultidrug resistance protein 1transporter
DB00715ParoxetineCytochrome P450 2B6enzyme
DB00715ParoxetineCytochrome P450 2C8enzyme
DB00715ParoxetineCytochrome P450 1A2enzyme
DB00715ParoxetineCytochrome P450 3A4enzyme
DB01224Quetiapine5-hydroxytryptamine receptor 2Atarget
DB01224Quetiapine5-hydroxytryptamine receptor 2Ctarget
DB01224QuetiapineD(2) dopamine receptortarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Atarget
DB01224QuetiapineHistamine H1 receptortarget
DB01224QuetiapineCytochrome P450 3A4enzyme
DB01224QuetiapineAlpha-1A adrenergic receptortarget
DB01224QuetiapineAlpha-1B adrenergic receptortarget
DB01224QuetiapineAlpha-1D adrenergic receptortarget
DB01224QuetiapineAlpha-2A adrenergic receptortarget
DB01224QuetiapineAlpha-2B adrenergic receptortarget
DB01224QuetiapineAlpha-2C adrenergic receptortarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Dtarget
DB01224QuetiapineMuscarinic acetylcholine receptor M1target
DB01224QuetiapineMuscarinic acetylcholine receptor M2target
DB01224QuetiapineMuscarinic acetylcholine receptor M3target
DB01224QuetiapineMuscarinic acetylcholine receptor M4target
DB01224QuetiapineMuscarinic acetylcholine receptor M5target
DB01224Quetiapine5-hydroxytryptamine receptor 1Btarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Etarget
DB01224Quetiapine5-hydroxytryptamine receptor 3Atarget
DB01224Quetiapine5-hydroxytryptamine receptor 6target
DB01224Quetiapine5-hydroxytryptamine receptor 7target
DB01224QuetiapineD(1B) dopamine receptortarget
DB01224QuetiapineD(1A) dopamine receptortarget
DB01224QuetiapineD(3) dopamine receptortarget
DB01224QuetiapineD(4) dopamine receptortarget
DB01224QuetiapineCytochrome P450 3A5enzyme
DB01224QuetiapineCytochrome P450 3A7enzyme
DB01224QuetiapineMultidrug resistance protein 1transporter
DB01224QuetiapineCytochrome P450 2C19enzyme
DB01224QuetiapineCytochrome P450 2D6enzyme
DB01104SertralineSodium-dependent serotonin transportertarget
DB01104SertralineCytochrome P450 2B6enzyme
DB01104SertralineCytochrome P450 2C19enzyme
DB01104SertralineCytochrome P450 2C9enzyme
DB01104SertralineCytochrome P450 2D6enzyme
DB01104SertralineSodium-dependent dopamine transportertarget
DB01104SertralineCYP2B proteinenzyme
DB01104SertralineCytochrome P450 3A4enzyme
DB01104SertralineAmine oxidase [flavin-containing] Benzyme
DB01104SertralineAmine oxidase [flavin-containing] Aenzyme
DB01104SertralineMultidrug resistance protein 1transporter
DB01104SertralineSerum albumincarrier
DB01104SertralineSigma receptortarget
DB01323St. John's WortMultidrug resistance protein 1transporter
DB01323St. John's WortCytochrome P450 3A4enzyme
DB01323St. John's WortCytochrome P450 2D6enzyme
DB01323St. John's WortCytochrome P450 2C19enzyme
DrugDrug NamePhaseStatusCount
DB06288Amisulpride1Completed1
DB00186Lorazepam1Recruiting1
DB00627Niacin1Recruiting1
DB00715Paroxetine1Completed1
DB00413Pramipexole1Completed1
DB11664Psilocybine1Recruiting2
DB01221Ketamine1 / 2Completed1
DB01221Ketamine1 / 2Terminated1
DB14009Medical Cannabis1 / 2Recruiting1
DB00683Midazolam1 / 2Terminated1
DB00486Nabilone1 / 2Completed1
DB01104Sertraline1 / 2Completed1
DB06151Acetylcysteine2Active Not Recruiting1
DB06151Acetylcysteine2Completed1
DB06151Acetylcysteine2Terminated1
DB00207Azithromycin2Completed1
DB01053Benzylpenicillin2Completed1
DB12426Bitopertin2Completed1
DB01242Clomipramine2Unknown Status1
DB00260Cycloserine2Completed1
DB00260Cycloserine2Unknown Status1
DB00260Cycloserine2Withdrawn1
DB00470Dronabinol2Completed1
DB01175Escitalopram2Completed1
DB01205Flumazenil2Terminated1
DB00472Fluoxetine2Terminated1
DB01221Ketamine2Active Not Recruiting1
DB01221Ketamine2Completed3
DB01221Ketamine2Recruiting1
DB01221Ketamine2Terminated1
DB00555Lamotrigine2Completed1
DB01043Memantine2Completed1
DB00683Midazolam2Active Not Recruiting1
DB00683Midazolam2Recruiting1
DB01017Minocycline2Completed1
DB01017Minocycline2Terminated1
DB00704Naltrexone2Terminated1
DB09152Nitrogen2Not Yet Recruiting1
DB06690Nitrous oxide2Not Yet Recruiting1
DB00904Ondansetron2Terminated1
DB00107Oxytocin2Completed1
DB01267Paliperidone2Completed1
DB01224Quetiapine2Completed1
DB11801Rapastinel2Completed1
DB00740Riluzole2Completed2
DB12519Sarcosine2Completed1
DB06369Secretin human2Completed1
DB01323St. John's Wort2Completed1
DB09315Xenon-1332Withdrawn1
DB01202Levetiracetam2 / 3Terminated1
DB01104Sertraline2 / 3Terminated1
DB00323Tolcapone2 / 3Recruiting1
DB01242Clomipramine3Completed1
DB00260Cycloserine3Completed2
DB01175Escitalopram3Completed1
DB00176Fluvoxamine3Completed2
DB01043Memantine3Completed1
DB01224Quetiapine3Completed1
DB01104Sertraline3Completed1
DB00273Topiramate3Completed1
DB01060Amoxicillin4Completed1
DB00215Citalopram4Completed1
DB00215Citalopram4Recruiting1
DB01242Clomipramine4Completed2
DB00260Cycloserine4Active Not Recruiting1
DB00260Cycloserine4Completed1
DB00476Duloxetine4Completed1
DB01175Escitalopram4Completed2
DB01175Escitalopram4Unknown Status2
DB00472Fluoxetine4Completed3
DB00472Fluoxetine4Recruiting1
DB00176Fluvoxamine4Recruiting1
DB00176Fluvoxamine4Terminated1
DB00176Fluvoxamine4Unknown Status1
DB00334Olanzapine4Completed1
DB00904Ondansetron4Completed2
DB00904Ondansetron4Recruiting1
DB00715Paroxetine4Completed1
DB00715Paroxetine4Recruiting1
DB00230Pregabalin4Recruiting1
DB00571Propranolol4Suspended1
DB01224Quetiapine4Completed3
DB01104Sertraline4Completed1
DB01104Sertraline4Recruiting2
DB01104Sertraline4Terminated1
DB00273Topiramate4Recruiting1
DB00273Topiramate4Unknown Status1
DB01238AripiprazoleNot AvailableCompleted1
DB01238AripiprazoleNot AvailableNot Yet Recruiting1
DB00215CitalopramNot AvailableRecruiting1
DB01242ClomipramineNot AvailableCompleted1
DB00260CycloserineNot AvailableCompleted3
DB00476DuloxetineNot AvailableActive Not Recruiting1
DB00476DuloxetineNot AvailableCompleted1
DB00476DuloxetineNot AvailableWithdrawn1
DB01175EscitalopramNot AvailableCompleted1
DB01175EscitalopramNot AvailableRecruiting1
DB00472FluoxetineNot AvailableActive Not Recruiting1
DB00472FluoxetineNot AvailableCompleted1
DB00472FluoxetineNot AvailableNot Yet Recruiting1
DB00472FluoxetineNot AvailableRecruiting1
DB00176FluvoxamineNot AvailableRecruiting3
DB00145GlycineNot AvailableCompleted1
DB01043MemantineNot AvailableCompleted1
DB00704NaltrexoneNot AvailableCompleted1
DB00715ParoxetineNot AvailableActive Not Recruiting1
DB00715ParoxetineNot AvailableRecruiting1
DB00734RisperidoneNot AvailableCompleted1
DB01104SertralineNot AvailableActive Not Recruiting1
DB01104SertralineNot AvailableRecruiting3
DB00285VenlafaxineNot AvailableActive Not Recruiting1
DB00246ZiprasidoneNot AvailableCompleted1